Greg M Delgoffe, PhD
- Associate Professor, Department of Immunology
- Member, University of Pittsburgh Cancer Institute
- Chair, Graduate Program in Microbiology and Immunology (PMI) Admissions Committee
- Member, Graduate Program in Microbiology and Immunology (PMI)
Education & Training
- Postdoc, St. Jude Children's Research Hospital
- PhD, Johns Hopkins University
- BS, Western Michigan University
The Delgoffe Lab studies the impact of the tumor microenvironment on T cell subsets that infiltrate the tumor. We aim to dissect how tumor cells promote an immunosuppressive environment through the modulation of metabolism. We are currently examining this from two major perspectives.
Immunometabolism of tumor-infiltrating Treg cells
Treg cells, while critical for preventing autoimmunity, provide a major barrier to antitumor immunity. Our studies suggest that tumors promote the function of these suppressive T cells by providing critical metabolic intermediates that support Treg cell function. We aim to dissect how different metabolites promote or inhibit Treg cell function generally, as well as determine whether these pathways can be targeted to relieve tumor-induced suppression and promote antitumor immunity.
Metabolic reprogramming of exhausted antitumor CTLs
Tumors provide chronic TCR stimulation to tumor-specific cytotoxic lymphocytes, as well as stimulation through co-inhibitory receptors. This results in a dysfunctional T cell phenotype known as T cell exhaustion. We hypothesize that T cell exhaustion is a metabolic phenotype, and that metabolism can be reprogrammed in tumor-specific CTLs to enhance their function, resulting in heightened antitumor responses.
Dr. Delgoffe is currently accepting graduate students for rotations in the laboratory, as well as applications for postdoctoral fellows.
Cancer Immunology Journal Club - University of Pittsburgh Cancer Institute
Dr. Delgoffe runs a journal club that meets on the most Wednesdays of every month at 5:00pm in the Second Floor Conference Room at the Hillman Cancer Center. We discuss any interesting, cool, or novel papers in the broad field of immunology and inflammation related to cancer. If you are interested in attending or presenting at the journal club, please email Dr. Delgoffe (firstname.lastname@example.org) to be added to our weekly mailing list.
Rivadeneira DB, DePeaux K, Wang Y, Kulkarni A, Tabib T, Menk AV, Sampath P, Lafyatis R, Ferris RL, Sarkar SN, Thorne SH and Delgoffe GM. 2019. Oncolytic Viruses Engineered to Enforce Leptin Expression Reprogram Tumor-Infiltrating T Cell Metabolism and Promote Tumor Clearance. Immunity. 51: 548-560 e4.
Najjar YG, Menk AV, Sander C, Rao U, Karunamurthy A, Bhatia R, Zhai S, Kirkwood JM and Delgoffe GM. 2019. Tumor cell oxidative metabolism as a barrier to PD-1 blockade immunotherapy in melanoma. JCI Insight. 4: pii: 124989. doi: 10.1172/jci.insight.124989.
Menk AV, Scharping NE, Rivadeneira DB, Calderon MJ, Watson MJ, Dunstane D, Watkins SC and Delgoffe GM. 2018. 4-1BB costimulation induces T cell mitochondrial function and biogenesis enabling cancer immunotherapeutic responses. J Exp Med. 215: 1091-1100.
Menk AV, Scharping NE, Moreci RS, Zeng X, Guy C, Salvatore S, Bae H, Xie J, Young HA, Wendell SG and Delgoffe GM. 2018. Early TCR Signaling Induces Rapid Aerobic Glycolysis Enabling Distinct Acute T Cell Effector Functions. Cell Rep. 22: 1509-1521.
Scharping NE, Menk AV, Whetstone RD, Zeng X and Delgoffe GM. 2017. Efficacy of PD-1 Blockade Is Potentiated by Metformin-Induced Reduction of Tumor Hypoxia. Cancer Immunol Res. 5: 9-16.